StockNews.AI

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

StockNews.AI • 11 hours

CRMDCLTXQURE
High Materiality10/10

Information

Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR  Combination achiev...

Original source

AI Summary

Pelareorep and atezolizumab achieved 29% ORR in third-line SCAC patients. The median DOR of 17 months shows significant clinical benefit. No FDA-approved therapies exist for third-line anal cancer patients. Oncolytics plans a registration study for accelerated FDA approval. Positive feedback from KOLs and FDA enhances developmental prospects.

Sentiment Rationale

The promising clinical data and proposed registration strategies typically boost investor confidence, similar to past announcements from biopharma companies that resulted in stock surges due to positive trial outcomes.

Trading Thesis

The planned Type C meeting with the FDA and discussions around accelerated approval indicate imminent stock movement due to potential regulatory updates.

Market-Moving

  • Pelareorep and atezolizumab achieved 29% ORR in third-line SCAC patients.
  • The median DOR of 17 months shows significant clinical benefit.
  • No FDA-approved therapies exist for third-line anal cancer patients.

Key Facts

  • Pelareorep and atezolizumab achieved 29% ORR in third-line SCAC patients.
  • The median DOR of 17 months shows significant clinical benefit.
  • No FDA-approved therapies exist for third-line anal cancer patients.
  • Oncolytics plans a registration study for accelerated FDA approval.
  • Positive feedback from KOLs and FDA enhances developmental prospects.

Companies Mentioned

  • CRMD (CRMD)
  • CLTX (CLTX)
  • QURE (QURE)

Research Analysis

The groundbreaking clinical results directly relate to Oncolytics' market potential and future revenue opportunities, making this news highly significant for stakeholders.

Oncolytics Biotech Inc. (Nasdaq: ONCY) Releases Promising Clinical Data for Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

On January 12, 2026, Oncolytics Biotech Inc. (Nasdaq: ONCY), a pioneering clinical-stage immunotherapy firm, announced updated clinical findings from its GOBLET Cohort 4 trial. The study investigated the efficacy of pelareorep, in combination with atezolizumab, for patients suffering from third-line metastatic squamous cell anal carcinoma (SCAC), a condition currently without any FDA-approved treatment options.

Key Findings from GOBLET Cohort 4

The latest data reveals that out of 14 evaluable patients in the third-line setting, four achieved objective responses, indicating an objective response rate (ORR) of approximately 29%. This achievement comprises two complete responses and two partial responses, showcasing the potential of pelareorep and atezolizumab to offer significant clinical benefits.

Crucially, the median duration of response (DOR) for these patients was found to be around 17 months (67 weeks), underscoring both the depth and durability of the treatment effects in a population heavily pretreated with other therapies. This is particularly promising when contrasted with historical benchmarks, where ORRs for third-line SCAC treatments typically hover around 10% or less.

Strategic Implications of the Results

Jared Kelly, CEO of Oncolytics, expressed optimism regarding the findings, stating, “As we continue to analyze the GOBLET data, we are finding important trends that are helping to shape our clinical development strategy. When you isolate to anal cancer patients with two prior lines of treatment and see a strong signal like this, it points the arrow in a direct line to a registration study in an indication where there are no FDA-approved therapies.”

In earlier studies, the combination of pelareorep and atezolizumab demonstrated a 30% ORR in the second-line setting, eclipsing the FDA's approved benchmark of 13.8% for the current standard of care. Moreover, the median duration of response was enhanced to 15.5 months, compared to 9.5 months for the existing treatments.

Future Prospects and Registration Strategy

Oncolytics plans to leverage the observed response rates and response durations from GOBLET Cohort 4 in its forthcoming registration study. If the impressive results are replicated, the firm anticipates that the data may be sufficient to support an accelerated approval pathway, following regulatory precedents for rare cancers lacking available therapies.

After receiving preliminary positive feedback from key opinion leaders (KOLs) and the FDA, Oncolytics is scheduled to hold a Type C meeting with the FDA in Q1 2026 to discuss and finalize its development strategy moving forward.

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc. is at the forefront of developing pelareorep, an innovative double-stranded RNA immunotherapeutic agent. The company is advancing multiple clinical programs, focusing on gastrointestinal cancers, including pancreatic and breast cancers, with indications of Fast Track designation from the FDA.

For more information on Oncolytics, visit www.oncolyticsbiotech.com or connect with the company on social media platforms such as LinkedIn and X (@oncolytics).

Forward-Looking Statements

This article contains forward-looking statements concerning Oncolytics and its products, including pelareorep. These statements involve risks and uncertainties that could cause actual results to differ from those anticipated. Investors are encouraged to consult the company's public filings for further information regarding potential risks.

Related News